Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2013

Open Access 01-12-2013 | Research article

Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method

Authors: Haibo Xu, Qinghe Wu, Cheng Peng, Lijuan Zhou

Published in: BMC Complementary Medicine and Therapies | Issue 1/2013

Login to get access

Abstract

Background

Seropharmacology arising recently is a novel method of in vitro pharmacological study on Chinese herb using drug-containing animal serum. As seropharmacology possesses the advantages of experiments in vitro and in vivo, it is increasingly applied in pharmacological research on Chinese medicine. However, some issues of seropharmacology remain controversial and need to be clearly defined. San Huang Yi Gan Capsule (SHYGC) is a Chinese herbal formula with antiviral property against hepatitis B virus (HBV), but little is known about the mechanism underlying its anti-HBV activity. The aim of the present study was to elucidate the action mechanism of SHYGC using seropharmacological method and systematically address the methodology of preparing drug-containing serum.

Methods

New Zealand rabbits were orally administrated SHYGC with various regimens, followed by preparation of SHYGC-containing rabbit sera with a variety of methods. After HBV-producing HepG2 2.2.15 cells were treated with SHYGC-containing sera or entecavir for 9 days, the levels of hepatitis B surface antigen (HBsAg) and HBV DNA and the activity of DNA Polymerase were determined in HepG2 2.2.15 cells-conditioned media.

Results

An optimally standardized method of preparing drug-containing serum was raised for seropharmacology, with which SHYGC was demonstrated to suppress HBsAg expression, HBV DNA replication and DNA Polymerase activity in a dose-dependent fashion.

Conclusions

This seropharmacological study shows SHYGC is a potentially powerful anti-HBV agent. Additionally, seropharmacology is a promising pharmacological method with a broad range of advantages, and it can be widely used in biomedical research, if combined with pharmacokinetics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bochu W, Liancai Z, Qi C: Primary study on the application of Serum Pharmacology in Chinese traditional medicine. Colloids Surf B Biointerfaces. 2005, 43 (3–4): 194-197.CrossRefPubMed Bochu W, Liancai Z, Qi C: Primary study on the application of Serum Pharmacology in Chinese traditional medicine. Colloids Surf B Biointerfaces. 2005, 43 (3–4): 194-197.CrossRefPubMed
2.
go back to reference Wu Q, Rong X, Huang P, Han J, Xu H: Study on inhibitory actions of san huang yi gan capsule (SHYGC) on HBeAg with seropharmacological method. Zhong Yao Cai. 2000, 23 (5): 275-278.PubMed Wu Q, Rong X, Huang P, Han J, Xu H: Study on inhibitory actions of san huang yi gan capsule (SHYGC) on HBeAg with seropharmacological method. Zhong Yao Cai. 2000, 23 (5): 275-278.PubMed
3.
go back to reference Zhang YH, Liu JT, Wen BY, Liu N: Mechanisms of inhibiting proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong pill. J Ethnopharmacol. 2009, 124 (1): 125-129. 10.1016/j.jep.2009.04.012.CrossRefPubMed Zhang YH, Liu JT, Wen BY, Liu N: Mechanisms of inhibiting proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong pill. J Ethnopharmacol. 2009, 124 (1): 125-129. 10.1016/j.jep.2009.04.012.CrossRefPubMed
4.
go back to reference Zhang H, Xing WW, Li YS, Zhu Z, Wu JZ, Zhang QY, Zhang W, Qin LP: Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts. Maturitas. 2008, 61 (4): 334-339. 10.1016/j.maturitas.2008.09.023.CrossRefPubMed Zhang H, Xing WW, Li YS, Zhu Z, Wu JZ, Zhang QY, Zhang W, Qin LP: Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts. Maturitas. 2008, 61 (4): 334-339. 10.1016/j.maturitas.2008.09.023.CrossRefPubMed
5.
go back to reference Sun J, Bi Y, Guo L, Qi X, Zhang J, Li G, Tian G, Ren F, Li Z: Buyang Huanwu Decoction promotes growth and differentiation of neural progenitor cells: using a serum pharmacological method. J Ethnopharmacol. 2007, 113 (2): 199-203. 10.1016/j.jep.2007.05.018.CrossRefPubMed Sun J, Bi Y, Guo L, Qi X, Zhang J, Li G, Tian G, Ren F, Li Z: Buyang Huanwu Decoction promotes growth and differentiation of neural progenitor cells: using a serum pharmacological method. J Ethnopharmacol. 2007, 113 (2): 199-203. 10.1016/j.jep.2007.05.018.CrossRefPubMed
7.
go back to reference Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009, 49 (5 Suppl): S103-111.CrossRefPubMed Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009, 49 (5 Suppl): S103-111.CrossRefPubMed
8.
go back to reference Fung J, Lai CL, Seto WK, Yuen MF: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011, 66 (12): 2715-2725. 10.1093/jac/dkr388.CrossRefPubMed Fung J, Lai CL, Seto WK, Yuen MF: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011, 66 (12): 2715-2725. 10.1093/jac/dkr388.CrossRefPubMed
9.
go back to reference Cox N, Tillmann H: Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs. 2011, 16 (4): 713-729. 10.1517/14728214.2011.646260.CrossRefPubMed Cox N, Tillmann H: Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs. 2011, 16 (4): 713-729. 10.1517/14728214.2011.646260.CrossRefPubMed
10.
go back to reference Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 1987, 84 (4): 1005-1009. 10.1073/pnas.84.4.1005.CrossRefPubMedPubMedCentral Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 1987, 84 (4): 1005-1009. 10.1073/pnas.84.4.1005.CrossRefPubMedPubMedCentral
11.
go back to reference Alexander GJ, Fagan EA, Rolando N, Guarner P, Callender ME, Eddleston AL, Williams R: Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection. A possible reason for lack of efficacy. J Hepatol. 1986, 3 (Suppl 2): S81-86.CrossRefPubMed Alexander GJ, Fagan EA, Rolando N, Guarner P, Callender ME, Eddleston AL, Williams R: Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection. A possible reason for lack of efficacy. J Hepatol. 1986, 3 (Suppl 2): S81-86.CrossRefPubMed
12.
go back to reference Samal J, Kandpal M, Vivekanandan P: Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012, 25 (1): 142-163. 10.1128/CMR.00018-11.CrossRefPubMedPubMedCentral Samal J, Kandpal M, Vivekanandan P: Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012, 25 (1): 142-163. 10.1128/CMR.00018-11.CrossRefPubMedPubMedCentral
13.
go back to reference Tang LL, Sheng JF, Xu CH, Liu KZ: Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res. 2009, 37 (3): 662-667. 10.1177/147323000903700308.CrossRefPubMed Tang LL, Sheng JF, Xu CH, Liu KZ: Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res. 2009, 37 (3): 662-667. 10.1177/147323000903700308.CrossRefPubMed
14.
go back to reference Tseng YP, Wu YC, Leu YL, Yeh SF, Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed). 2010, 2: 1538-1547. Tseng YP, Wu YC, Leu YL, Yeh SF, Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed). 2010, 2: 1538-1547.
15.
go back to reference Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D: Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull. 2009, 32 (1): 132-135. 10.1248/bpb.32.132.CrossRefPubMed Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D: Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull. 2009, 32 (1): 132-135. 10.1248/bpb.32.132.CrossRefPubMed
16.
go back to reference Loo WT, Cheung MN, Chow LW: Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed Pharmacother. 2007, 61 (9): 606-610. 10.1016/j.biopha.2007.08.023.CrossRefPubMed Loo WT, Cheung MN, Chow LW: Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed Pharmacother. 2007, 61 (9): 606-610. 10.1016/j.biopha.2007.08.023.CrossRefPubMed
17.
go back to reference Li Z, Li LJ, Sun Y, Li J: Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy. 2007, 53 (5): 320-326. 10.1159/000107690.CrossRefPubMed Li Z, Li LJ, Sun Y, Li J: Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy. 2007, 53 (5): 320-326. 10.1159/000107690.CrossRefPubMed
18.
go back to reference Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH: Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res. 2001, 15 (8): 718-720. 10.1002/ptr.832.CrossRefPubMed Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH: Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res. 2001, 15 (8): 718-720. 10.1002/ptr.832.CrossRefPubMed
19.
go back to reference Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002, 46 (8): 2525-2532. 10.1128/AAC.46.8.2525-2532.2002.CrossRefPubMedPubMedCentral Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002, 46 (8): 2525-2532. 10.1128/AAC.46.8.2525-2532.2002.CrossRefPubMedPubMedCentral
20.
go back to reference Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 1999, 43 (1): 190-193.PubMedPubMedCentral Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 1999, 43 (1): 190-193.PubMedPubMedCentral
21.
go back to reference Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997, 41 (7): 1444-1448.PubMedPubMedCentral Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997, 41 (7): 1444-1448.PubMedPubMedCentral
Metadata
Title
Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method
Authors
Haibo Xu
Qinghe Wu
Cheng Peng
Lijuan Zhou
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2013
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-13-239

Other articles of this Issue 1/2013

BMC Complementary Medicine and Therapies 1/2013 Go to the issue